Hyperactivation of PI3K/AKT and MAPK signaling caused by EGFR mutations can stimulate proliferation, invasion, and migration abilities of cancer cells20–23, with these effects being suppressed by PI3K and MEK inhibitors24. This evidence concerns the gene EGFR and cancer.